Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]

• Awaiting development
• Reference number: GID-TA11516
• Expected publication date:  06 May 2027